The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Approval Alert | Sotorasib/Panitumumab in KRAS G12C-Mutated Colorectal Cancer
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Adding panitumumab to sotorasib has yielded higher responses rates in KRAS G12C-mutated CRC compared with prior standards of care.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Pertuzumab Biosimilar in Breast Cancer Indications
2
AVZO-1418/DB-1418 Earns FDA Fast Track Designation For EGFR-Mutated NSCLC
3
Scorpion Venom Approach May Prove “Powerful” in Glioblastoma Research
4
FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs
5
